[go: up one dir, main page]

AR038605A1 - Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento - Google Patents

Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento

Info

Publication number
AR038605A1
AR038605A1 ARP030100608A ARP030100608A AR038605A1 AR 038605 A1 AR038605 A1 AR 038605A1 AR P030100608 A ARP030100608 A AR P030100608A AR P030100608 A ARP030100608 A AR P030100608A AR 038605 A1 AR038605 A1 AR 038605A1
Authority
AR
Argentina
Prior art keywords
treatment
manufacture
inflammation
agent
agents
Prior art date
Application number
ARP030100608A
Other languages
English (en)
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27767592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR038605(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of AR038605A1 publication Critical patent/AR038605A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G01N2333/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)

Abstract

Uso de un agente que se liga en forma específica a una alfa-4 integrina o a un dímero que comprende una alfa-4 integrina para la manufactura de un medicamento para la reducción crónica de la inflamación patológica de un paciente. El agente proporcionado debe tener una afinidad de enlace de manera tal que la administración es suficiente para suprimir la inflamación patológica, y el agente se administra en forma crónica para proporcionar la supresión a largo plazo de la inflamación patológica. Reivindicación 33: La composición de cualquiera de las reivindicaciones 30 ó 31, en donde el agente es natalizumab.
ARP030100608A 2002-02-25 2003-02-25 Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento AR038605A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36013402P 2002-02-25 2002-02-25
US37450102P 2002-04-23 2002-04-23

Publications (1)

Publication Number Publication Date
AR038605A1 true AR038605A1 (es) 2005-01-19

Family

ID=27767592

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030100608A AR038605A1 (es) 2002-02-25 2003-02-25 Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento

Country Status (28)

Country Link
US (7) US20040009169A1 (es)
EP (6) EP2289941A3 (es)
JP (3) JP2005526045A (es)
KR (1) KR20040105740A (es)
CN (1) CN1310678C (es)
AR (1) AR038605A1 (es)
AT (1) ATE512163T1 (es)
AU (2) AU2003213231A1 (es)
BR (1) BR0307975A (es)
CA (1) CA2477178A1 (es)
CO (1) CO5611176A2 (es)
CY (1) CY1111787T1 (es)
DK (2) DK2336184T3 (es)
ES (1) ES2531852T3 (es)
IL (3) IL163725A0 (es)
MX (1) MXPA04008267A (es)
MY (1) MY157727A (es)
NO (1) NO336235B1 (es)
NZ (3) NZ579583A (es)
PH (1) PH12020500242A1 (es)
PL (1) PL215263B1 (es)
PT (2) PT2336184E (es)
RU (1) RU2359697C2 (es)
SA (1) SA03240276A (es)
SI (2) SI2336184T1 (es)
TW (2) TWI346558B (es)
WO (1) WO2003072040A2 (es)
ZA (1) ZA200407406B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215263B1 (pl) 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
EP2336185A1 (en) 2002-03-13 2011-06-22 Biogen Idec Inc. Anti- alpha v beta 6 antibodies
KR20050114212A (ko) * 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
WO2005000244A2 (en) 2003-06-25 2005-01-06 Elan Pharmaceuticals, Inc. Methods and compositions for treating rheumatoid arthritis
CN1956738B (zh) 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
NZ584288A (en) * 2004-02-06 2011-10-28 Elan Pharm Inc Methods and compositions for treating tumors and metastatic disease
MY162179A (en) 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
AU2011213878B2 (en) * 2004-04-01 2012-06-14 Biogen Ma Inc. Steroid sparing agents and methods of using same
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
AU2011232775B2 (en) * 2004-08-20 2013-11-28 Biogen Ma Inc. Extended Treatment of Multiple Sclerosis
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
AU2012202575B2 (en) * 2004-11-19 2014-11-20 Biogen Ma Inc. Treatment for Multiple Sclerosis
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
ATE431740T1 (de) * 2004-12-22 2009-06-15 Merck Serono Sa Kombinationstherapie gegen multiple sklerose
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
AU2012202823B2 (en) * 2005-04-04 2014-09-25 Biogen Ma Inc. Methods and Products for Evaluating an Immune Response to a Therapeutic Protein
DK2645106T4 (da) 2005-04-04 2024-12-02 Biogen Ma Inc Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007007160A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007100770A2 (en) 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab
US8410115B2 (en) * 2006-02-28 2013-04-02 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with alpha-4 inhibitory compounds
RS20080391A (sr) * 2006-03-03 2009-07-15 Elan Pharmaceuticals Inc., Postupci lečenja zapaljenskih i autoimunih bolesti natalizumabom
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
US20110184747A1 (en) * 2006-08-09 2011-07-28 Carmen Bozic Method for distribution of a drug
WO2008140602A2 (en) 2006-12-07 2008-11-20 The Govenment Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services USE OF ANTAGONISTS OF THE INTERACTION BETWEEN HIV GP120 AND α4β7 INTEGRIN
BRPI0901298A2 (pt) 2009-04-06 2011-01-04 Ems Sa derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
SG175166A1 (en) * 2009-04-17 2011-11-28 Biogen Idec Inc Compositions and methods to treat acute myelogenous leukemia
WO2011020874A1 (en) * 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
JP2013507618A (ja) 2009-10-11 2013-03-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド 抗ｖｌａ‐４関連アッセイ
RS63744B1 (sr) 2010-01-11 2022-12-30 Biogen Ma Inc Test za antitela protiv jc virusa
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
PT2558499T (pt) 2010-04-16 2017-07-14 Biogen Ma Inc Anticorpos anti-vla-4
JP5847188B2 (ja) 2010-10-25 2016-01-20 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． ｓＶＣＡＭおよび／またはｓＭＡｄＣＡＭレベルの差を関連付けることにより、アルファ−４インテグリン活性の差を決定するための方法
CN109734807A (zh) * 2011-03-31 2019-05-10 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
KR101875155B1 (ko) 2011-05-02 2018-07-09 밀레니엄 파머슈티컬스 인코퍼레이티드 항-α4β7 항체에 대한 제형
ES2729945T3 (es) 2011-05-31 2019-11-07 Biogen Ma Inc Procedimiento para valorar el riesgo de LMP
ES2655676T3 (es) * 2012-01-12 2018-02-21 Pharma Two B Ltd. Terapia de combinación con dosis fijas para tratar la enfermedad de Parkinson
EP2928374B1 (en) * 2012-12-05 2019-07-24 Theranos IP Company, LLC Device for bodily fluid sample collection
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
HK1216546A1 (zh) 2013-05-28 2016-11-18 Biogen Ma Inc. 评估pml风险的方法
WO2015051152A1 (en) * 2013-10-03 2015-04-09 Leuvas Therapeutics Modulation of leukocyte activity in treatment of neuroinflammatory degenerative disease
US9763992B2 (en) 2014-02-13 2017-09-19 Father Flanagan's Boys' Home Treatment of noise induced hearing loss
RU2693463C2 (ru) * 2014-04-04 2019-07-03 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта
CN106573065A (zh) * 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
JP2018507868A (ja) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド インテグリンベータ７アンタゴニスト及びクローン病の治療方法
EP3362080A1 (en) * 2015-10-16 2018-08-22 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an nmda modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
KR20180123214A (ko) * 2015-12-09 2018-11-15 난트 홀딩스 아이피, 엘엘씨 Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
EP3655011A4 (en) * 2017-07-20 2021-03-31 University Of Virginia Patent Foundation PROCEDURES FOR THE TREATMENT OR PREVENTION OF A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM
EP3773573A4 (en) 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
US20210147547A1 (en) * 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
US12037398B2 (en) 2018-06-04 2024-07-16 Biogen Ma Inc. Anti-VLA-4 antibodies having reduced effector function
WO2020112773A1 (en) * 2018-11-27 2020-06-04 The General Hospital Corporation Targeting intraepithelial lymphocytes for treatment of metabolic syndrome
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7
WO2022160323A1 (zh) * 2021-01-31 2022-08-04 兰州大学 核苷类似物在制备预防或治疗胃肠道疾病药物中的应用
EP4323407A1 (en) 2021-04-13 2024-02-21 Biogen MA Inc. Compositions and methods for treating chronic active white matter lesions / radiologically isolated syndrome
US20240350494A1 (en) * 2021-09-03 2024-10-24 Pliant Therapeutics, Inc. Therapeutic modulation of integrins
AU2024282654A1 (en) 2023-05-30 2025-12-04 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
JPH037237A (ja) * 1989-03-14 1991-01-14 Sandoz Ag シクロスポリン類投与の新規用途および治療手段
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US5260210A (en) * 1989-09-27 1993-11-09 Rubin Lee L Blood-brain barrier model
US6033665A (en) * 1989-09-27 2000-03-07 Elan Pharmaceuticals, Inc. Compositions and methods for modulating leukocyte adhesion to brain endothelial cells
SE464961B (sv) 1989-11-15 1991-07-08 Volvo Ab Ledprotes, i synnerhet foer fingerleder
DE59008157D1 (de) 1989-11-20 1995-02-09 Wolfgang Becker Verfahren zur herstellung einer zahnprothese.
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
DK0531472T3 (da) 1991-03-06 2003-12-01 Merck Patent Gmbh Humaniserede monoklonale antistoffer
US6225447B1 (en) 1991-05-15 2001-05-01 Cambridge Antibody Technology Ltd. Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5224539A (en) 1991-06-14 1993-07-06 Coen Company, Inc. Cooling system for air heaters and the like
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
EP0625912B1 (en) 1992-02-12 1997-04-16 Biogen, Inc. Treatment for inflammatory bowel disease
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5336894A (en) 1992-04-21 1994-08-09 The United States Of America As Represented By The Secretary Of The Air Force Universal infrared heat source controller
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
DK0678122T3 (da) 1993-01-12 2000-03-06 Biogen Inc Rekombinante anti-VLA4 antistofmolekyler
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
JP4115517B2 (ja) 1994-01-25 2008-07-09 エラン ファーマシューティカルズ， インコーポレイテッド 白血球付着分子 ｖｌａ−４に対するヒト化抗体
GB9406974D0 (en) 1994-04-08 1994-06-01 Pharmaceutical Proteins Ltd Transgenic production
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6001809A (en) 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
DE69530392D1 (de) 1994-07-11 2003-05-22 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP1281718A3 (en) 1995-11-10 2005-01-19 ELAN CORPORATION, Plc Peptides which enhance transport across tissues
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
IL119989A0 (en) 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1005368B1 (en) 1997-03-10 2009-09-02 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide in combination with alum as adjuvants
JP2001517245A (ja) 1997-05-29 2001-10-02 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としてのビアリールアルカン酸類
EP1148889A2 (en) 1999-01-29 2001-10-31 Millennium Pharmaceuticals, Inc. Method of treating demyelinating inflammatory disease using ccr1 antagonists
US6387930B1 (en) * 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP1294770B1 (en) 2000-05-10 2011-12-07 Mayo Foundation For Medical Education And Research Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
KR20050114212A (ko) * 2003-01-24 2005-12-05 엘란 파마슈티칼스, 인크. 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
ZA200506159B (en) * 2003-02-10 2006-10-25 Elan Pharm Inc Immunoglobulin formulation and method of preparation thereof
US7163939B2 (en) 2003-11-05 2007-01-16 Abbott Laboratories Macrocyclic kinase inhibitors
NZ581497A (en) * 2004-12-03 2012-07-27 Biogen Idec Inc Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody
WO2006112951A2 (en) * 2005-03-03 2006-10-26 Seedlings Life Science Ventures, Llc Method of risk management for patients undergoing natalizumab treatment
DK2645106T4 (da) * 2005-04-04 2024-12-02 Biogen Ma Inc Fremgangsmåder til evaluering af et immunrespons på et terapeutisk middel
WO2007100770A2 (en) * 2006-02-28 2007-09-07 Elan Pharmaceuticals, Inc. Methods of treating inflammatory and autoimmune diseases with natalizumab

Also Published As

Publication number Publication date
EP2289941A3 (en) 2012-01-18
IL203515A (en) 2015-10-29
RU2004128454A (ru) 2005-05-10
CY1111787T1 (el) 2015-10-07
PL215263B1 (pl) 2013-11-29
NZ579583A (en) 2011-04-29
EP2336184A2 (en) 2011-06-22
MY157727A (en) 2016-07-15
US20110064729A1 (en) 2011-03-17
PT1485127E (pt) 2011-09-07
AU2009201587B2 (en) 2012-01-19
TWI346558B (en) 2011-08-11
IL163725A (en) 2013-07-31
SI2336184T1 (sl) 2015-04-30
US20170306026A1 (en) 2017-10-26
CN1646163A (zh) 2005-07-27
KR20040105740A (ko) 2004-12-16
AU2009201587A1 (en) 2009-05-14
JP2011140493A (ja) 2011-07-21
DK1485127T3 (da) 2011-10-03
JP2015042629A (ja) 2015-03-05
EP1485127B1 (en) 2011-06-08
PH12020500242A1 (en) 2023-03-20
JP2005526045A (ja) 2005-09-02
EP3173426A1 (en) 2017-05-31
MXPA04008267A (es) 2004-11-10
NZ591635A (en) 2012-06-29
EP3674322A1 (en) 2020-07-01
US20200148773A1 (en) 2020-05-14
TW200400047A (en) 2004-01-01
EP1485127A4 (en) 2006-02-01
US20070025989A1 (en) 2007-02-01
CA2477178A1 (en) 2003-09-04
RU2359697C2 (ru) 2009-06-27
BR0307975A (pt) 2005-01-11
US20040009169A1 (en) 2004-01-15
WO2003072040A3 (en) 2004-05-21
NZ535320A (en) 2008-05-30
PT2336184E (pt) 2015-03-09
TW201125584A (en) 2011-08-01
NO20044054L (no) 2004-11-24
ES2531852T3 (es) 2015-03-20
ZA200407406B (en) 2005-11-30
WO2003072040A2 (en) 2003-09-04
US11248051B2 (en) 2022-02-15
US20150152182A1 (en) 2015-06-04
EP2336184A3 (en) 2012-01-11
IL163725A0 (en) 2005-12-18
DK2336184T3 (en) 2015-02-16
CN1310678C (zh) 2007-04-18
EP2360185A3 (en) 2012-01-11
HK1073997A1 (en) 2005-10-28
SI1485127T1 (sl) 2011-09-30
AU2003213231A1 (en) 2003-09-09
US20220162321A1 (en) 2022-05-26
EP2360185A2 (en) 2011-08-24
PL372306A1 (pl) 2005-07-11
CO5611176A2 (es) 2006-02-28
EP2289941A2 (en) 2011-03-02
SA03240276A (ar) 2005-12-03
ATE512163T1 (de) 2011-06-15
EP1485127A2 (en) 2004-12-15
US7807167B2 (en) 2010-10-05
EP2336184B1 (en) 2014-12-03
NO336235B1 (no) 2015-06-22

Similar Documents

Publication Publication Date Title
AR038605A1 (es) Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
BRPI0410260A (pt) composição conjugada para medicamento
DK1079807T3 (da) Anvendelse af præparater til tilförsel af antiseptiske midler og/eller midler, som fremmer heling af sår, til de nedre luftveje
AR032556A1 (es) Medicamento de accion inmediata para el tratamiento de la disfuncion sexual
AR027391A1 (es) Composiciones farmaceuticas de toxina botulinica
ECSP099387A (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos de utilidad en el tratamiento de trastornos hiperproliferativos y enfermedades asociadas con la angiogénesis
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
AR109263A2 (es) Composición que comprende moxidectina
ES2250416T3 (es) Estimulante de secreciohn de hormona de crecimiento.
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
PE20020387A1 (es) Uso de una combinacion de salmeterol y fluticasona
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
AR036321A1 (es) Metodo y formulacion farmaceutica para el tratamiento de la discinesia de aparicion tardia.
RU2007138263A (ru) Противовоспалительные соединения
MXPA05009849A (es) Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2.
AR038632A1 (es) Composicion farmaceutica
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
TW200501967A (en) Nemorubicin for use in the preparation of a medicament for liver disease
UY27688A1 (es) Administración de agentes para el tratamiento de la inflamación .
IL183924A0 (en) Use of a combination of active agents in the preparation of pharmaceutical compositions
BRPI0407174A (pt) Regime de administração para nelfinavir

Legal Events

Date Code Title Description
FA Abandonment or withdrawal